immuno oncology frontiers world miami


Alessandra Polara

Alessandra Polara

BD&L Director, Roche Partnering

Alessandra Polara, PhD, is the Business Development & Licensing Director in Roche Partnering leading Roche/Genentech efforts for partnered clinical collaborations deals in oncology. Since joining Roche Partnering in 2012, Dr Polara has a played a pivotal role in identifying and negotiating licensing and collaboration deals in the Cancer Immunotherapy space.

Dr Polara received her PhD in Organic Chemistry from the University of Cambridge and postdoctoral training as a Marie Curie Research Fellow at Columbia University and University of Cambridge.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy